EBF3 and metastatic neoplasm: Promoter hypermethylation and elevated mRNA levels of EBF3 were validated in an independent melanoma cohort (data generated by Marzese et al. [11, 12]) and in The Cancer Genome Atlas melanoma dataset (TCGA SKCM), which contains data for 458 patients (99 primary and 359 metastatic tumours) [9].